Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
PUT
Flutter Entertainment
FLUT
$17.2B
| $31.5M | 0.01% |
146,600
+126,600
| +633% | +$28.5M |
|
1002
PUT
Ross Stores
ROST
$80.8B
| $31.5M | 0.01% |
+175,000
| New | +$29.2M |
|
1003
Builders FirstSource
BLDR
$8.08B
| $31.4M | 0.01% |
305,110
-57,899
| -16% | -$6.51M |
|
1004
CAVA Group
CAVA
$7.08B
| $31.4M | 0.01% |
534,517
+237,323
| +80% | +$13.2M |
|
1005
PUT
Rivian
RIVN
$23.7B
| $31.4M | 0.01% |
1,591,000
-2,009,900
| -56% | -$31.9M |
|
1006
First Citizens BancShares
FCNCA
$25.4B
| $31.1M | 0.01% |
14,491
-12,514
| -46% | -$23.6M |
|
1007
TriNet
TNET
$3.06B
| $31M | 0.01% |
524,650
+62,704
| +14% | +$3.73M |
|
1008
Hims & Hers Health
HIMS
$7.06B
| $31M | 0.01% |
953,471
+294,500
| +45% | +$12.6M |
|
1009
Enphase Energy
ENPH
$5.59B
| $30.9M | 0.01% |
963,515
-37,460
| -4% | -$1.21M |
|
1010
Zions Bancorporation
ZION
$10.4B
| $30.8M | 0.01% |
526,674
-216,704
| -29% | -$11.8M |
|
1011
PUT
Ford
F
$55.7B
| $30.8M | 0.01% |
2,347,600
+281,300
| +14% | +$3.63M |
|
|
1012
CALL
Gilead Sciences
GILD
$168B
| $30.7M | 0.01% |
250,500
| – | – |
|
1013
Progress Software
PRGS
$1.77B
| $30.7M | 0.01% |
715,691
+200,692
| +39% | +$8.75M |
|
1014
Sunoco
SUN
$13.8B
| $30.5M | 0.01% |
582,140
-11,830
| -2% | -$625K |
|
1015
CALL
Airbnb
ABNB
$111B
| $30.5M | 0.01% |
224,700
+174,500
| +348% | +$21.7M |
|
1016
Taysha Gene Therapies
TSHA
$1.92B
| $30.5M | 0.01% |
5,539,001
+390,889
| +8% | +$1.9M |
|
|
BA.PRA
1017
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
$8.24B
| $30.5M | 0.01% |
441,084
-276,077
| -38% | -$18.5M |
|
1018
JD.com
JD
$43.1B
| $30.4M | 0.01% |
1,060,572
+128,986
| +14% | +$4.03M |
|
1019
PUT
State Street SPDR S&P Bank ETF
KBE
$1.73B
| $30.3M | 0.01% |
+500,000
| New | +$29.5M |
|
1020
CALL
Yum China
YUMC
$16.3B
| $30.3M | 0.01% |
635,000
-30,000
| -5% | -$1.37M |
|
1021
CALL
Lamb Weston
LW
$7.23B
| $30.2M | 0.01% |
+721,900
| New | +$42.5M |
|
1022
PUT
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.1B
| $30.2M | 0.01% |
+50,000
| New | +$29.9M |
|
1023
Clorox
CLX
$13.1B
| $30.1M | 0.01% |
298,718
-96,720
| -24% | -$10.5M |
|
1024
Progyny
PGNY
$2.04B
| $30.1M | 0.01% |
1,172,436
-403,034
| -26% | -$9.27M |
|
1025
Kratos Defense & Security Solutions
KTOS
$12B
| $30.1M | 0.01% |
396,129
-17,385
| -4% | -$1.42M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.